Eris Lifesciences acquires anti-diabetes drug Zomelis from Novartis for $13 million
Updated : December 04, 2019 11:20 AM IST
Eris Lifesciences acquired the trademark for anti-diabetes drug Zomelis from Novartis AG for a consideration of $13 million.
The company will start selling the drug in the Indian market from December 10 onwards.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more